Pneumology Group, Dept of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, P.R. China Center for Asthma and Respiratory Diseases, Dept of Respiratory and Sleep Medicine, John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle, New Lambton, NSW, Australia.
Center for Asthma and Respiratory Diseases, Dept of Respiratory and Sleep Medicine, John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle, New Lambton, NSW, Australia
Eur Respir J. 2016 Apr;47(4):1123-33. doi: 10.1183/13993003.01098-2015. Epub 2015 Dec 23.
Mast cells are a resident inflammatory cell of the airways, involved in both the innate and adaptive immune response. The relationship between mast cells and inflammatory phenotypes and treatment response of asthma is not clear.Clinical characteristics of subjects with stable asthma (n=55), inflammatory cell counts and gene expression microarrays in induced sputum were analysed. Sputum mast cell subtypes were determined by molecular phenotyping based on expression of mast cell biomarkers (tryptase (TPSAB1), chymase (CMA1) and carboxypeptidase A3 (CPA3)). Effects of mast cell subtypes on steroid response were observed in a prospective cohort study (n=50).MCT(n=18) and MCT/CPA3(mRNA expression of TPSAB1 and CPA3; n=29) subtypes were identified, as well as a group without mast cell gene expression (n=8). The MCT/CPA3 subtype had elevated exhaled nitric oxide fraction, sputum eosinophils, bronchial sensitivity and reactivity, and poorer asthma control. This was accompanied by upregulation of 13 genes. Multivariable logistic regression identified CPA3(OR 1.21, p=0.004) rather than TPSAB1(OR 0.92, p=0.502) as a determinant of eosinophilic asthma. The MCT/CPA3 subtype had a better clinical response and reduced signature gene expression with corticosteroid treatment.Sputum mast cell subtypes of asthma can be defined by a molecular phenotyping approach. The MCT/CPA3 subtype demonstrated increased bronchial sensitivity and reactivity, and signature gene expression, which was associated with airway eosinophilia and greater corticosteroid responsiveness.
肥大细胞是气道中的常驻炎性细胞,参与固有和适应性免疫反应。肥大细胞与哮喘的炎症表型和治疗反应之间的关系尚不清楚。对 55 例稳定期哮喘患者(n=55)的临床特征、诱导痰中炎性细胞计数和基因表达微阵列进行了分析。根据肥大细胞生物标志物(类胰蛋白酶(TPSAB1)、糜蛋白酶(CMA1)和羧肽酶 A3(CPA3)的表达)进行分子表型确定痰中肥大细胞亚型。在一项前瞻性队列研究(n=50)中观察了肥大细胞亚型对类固醇反应的影响。鉴定了 MCT(n=18)和 MCT/CPA3(TPSAB1 和 CPA3 的 mRNA 表达;n=29)亚型,以及一组没有肥大细胞基因表达的组(n=8)。MCT/CPA3 亚型呼气一氧化氮分数、痰嗜酸性粒细胞、支气管敏感性和反应性升高,哮喘控制较差。这伴随着 13 个基因的上调。多变量逻辑回归确定 CPA3(OR 1.21,p=0.004)而不是 TPSAB1(OR 0.92,p=0.502)是嗜酸性哮喘的决定因素。MCT/CPA3 亚型在皮质类固醇治疗后具有更好的临床反应和减少的特征基因表达。通过分子表型方法可以定义哮喘的痰肥大细胞亚型。MCT/CPA3 亚型表现出增加的支气管敏感性和反应性,以及特征性基因表达,这与气道嗜酸性粒细胞增多和更大的皮质类固醇反应性相关。